OBJECTIVES: This descriptive study aimed to evaluate the clinical characteristics and identify the main treatments patterns and biomarkers performed in patients with early-stage NSCLC using the SMEO database.

METHODS: This is a retrospective database analysis of the SMEO (Mexican Society of Clinical Oncology) database in patients with IB, II, or IIIA NSCLC who underwent surgery diagnosed January 01, 2016 and December 31,2019. Clinical and epidemiological features were assessed, measures of central tendency and dispersion were presented for quantitative variables and frequencies for qualitative variables.

RESULTS: the analysis included a total of 105 patients with a mean age of 64.7 years old,76.0% had a histological diagnosis of adenocarcinoma NSCLC and 21.1% of epidermoid NSCLC; most of the patients (66.3%) were in stage IIIA, followed by stage I (19.2%). A similar distribution was observed between female and male patients in the age group 50 to 69 years. The most common comorbidities were arterial hypertension and diabetes. The smoking index were 48.5 in squamous group vs 15.1 in non-squamous group (p=0.0002,T-test) and contact with asbestos by year were higher in squamous (12.0) vs non-squamous histology (1.9) (p=004,T-test). Regarding treatment patterns, 74.0% received initial treatment recorded in the database. Of these, most of them received chemotherapy (87%). The three most used first-line chemotherapy treatments were Paclitaxel+Carboplatin (47.4%), Pemetrexed + Carboplatin (16.4%), and Gefitinib (5.06%). 38.9% of the patient records had reports of recurrence. Regarding the biomarker testing, it was performed in 54 non-squamous NSCLC patients, 17.7% were EGFR mutated and 2.4% ALK mutated. No PDL-1 testing was performed.

CONCLUSIONS: A higher smoking index and asbestos by year in the squamous histology vs non squamous one was found, most common treatment received as first line were chemotherapy, this is the first study in Mexico addressing clinical and treatment patterns in early lung cancer.